{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:29:33Z","timestamp":1779377373328,"version":"3.53.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Genetic variation has been considered a major contributor to the high variability in the response to dual antiplatelet therapy in patients with acute ischemic stroke or transient ischemic attack. Recently, incidences of ischemic stroke are increasing rapidly in China. We aimed to evaluate the influence of potential determinants on the response of antiplatelet therapy and adverse events in Chinese ischemic stroke patients receiving clopidogrel-aspirin treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Based on the clopidogrel drug response pathway and the coagulation and anticoagulation function, we systematically selected 34 genetic polymorphisms in 12 candidate genes. Three hundred and eight patients were divided into 2 groups according to their degree of inhibition of platelet aggregation. Multivariate analysis was then performed to assess the influence of demographic, clinical and genetic factors on platelet reactivity in Chinese ischemic stroke patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We found that polymorphisms in <jats:italic toggle=\"yes\">CYP2C19<\/jats:italic> and <jats:italic toggle=\"yes\">F2R<\/jats:italic> genes were still significantly associated with platelet reactivity in Chinese ischemic stroke patients (<jats:italic toggle=\"yes\">P =<\/jats:italic> 0.037 and 0.015). The newly identified rs168753 in <jats:italic toggle=\"yes\">F2R<\/jats:italic> gene may influence the efficacy to clopidogrel-aspirin therapy for ischemic stroke patients. We also found that ischemic stroke patients with low level of inhibition of platelet aggregation had higher risk of recurrent ischemic events (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Together, these results emphasized the necessity of genotype-directed antiplatelet therapy and facilitated to minimize adverse ischemic events.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000462","type":"journal-article","created":{"date-parts":[[2021,12,26]],"date-time":"2021-12-26T17:01:33Z","timestamp":1640538093000},"page":"138-143","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Associations of CYP2C19 and F2R genetic polymorphisms with platelet reactivity in Chinese ischemic stroke patients receiving clopidogrel therapy"],"prefix":"10.1097","volume":"32","author":[{"given":"Suli","family":"Zhang","sequence":"first","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengzhen","family":"Li","sequence":"additional","affiliation":[{"name":"Laigang Hospital, Laiwu, Shandong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Shanghai Baio Technology Co., Ltd., Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, 305 Hospital of People\u2019s Liberation Army, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxin","family":"Fang","sequence":"additional","affiliation":[{"name":"Shandong Provincial Third Hospital, Shandong and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengying","family":"Qin","sequence":"additional","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University"},{"name":"The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"R1-20250808","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10072-020-04797-5","article-title":"Cumulative risk of stroke recurrence over the last 10 years: a systematic review and meta-analysis.","volume":"42","author":"Lin","year":"2021","journal-title":"Neurol Sci"},{"key":"R2-20250808","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/0091270009332433","article-title":"Clopidogrel resistance: pharmacokinetic or pharmacogenetic?","volume":"49","author":"Ford","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"R3-20250808","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jvs.2015.12.020","article-title":"Dual antiplatelet therapy reduces stroke but increases bleeding at the time of carotid endarterectomy.","volume":"63","author":"Jones","year":"2016","journal-title":"J Vasc Surg"},{"key":"R4-20250808","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2174\/1389200221666200110153304","article-title":"Effect of environmental exposure and pharmacogenomics on drug metabolism.","volume":"20","author":"Banerjee","year":"2019","journal-title":"Curr Drug Metab"},{"key":"R5-20250808","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.dmpk.2015.05.003","article-title":"The impact of genetic polymorphisms of drug metabolizing enzymes on the pharmacodynamics of clopidogrel under steady state conditions.","volume":"30","author":"Nakkam","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"key":"R6-20250808","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00228-012-1381-8","article-title":"Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.","volume":"69","author":"Subraja","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R7-20250808","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events.","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"R8-20250808","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/ehjcvp\/pvz045","article-title":"Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.","volume":"6","author":"Lewis","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R9-20250808","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1517\/17425255.2015.1068757","article-title":"The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.","volume":"11","author":"Yang","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R10-20250808","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/FPC.0000000000000400","article-title":"Identification of populations likely to benefit from pharmacogenomic testing.","volume":"30","author":"Craig","year":"2020","journal-title":"Pharmacogenet Genomics"},{"key":"R11-20250808","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FPC.0000000000000438","article-title":"Analytical validation of a laboratory-development multigene pharmacogenetic assay.","volume":"31","author":"Roc\u00edo","year":"2021","journal-title":"Pharmacogenet Genomics"},{"key":"R12-20250808","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jacc.2013.01.015","article-title":"Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) study.","volume":"61","author":"Patti","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R13-20250808","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/FPC.0000000000000272","article-title":"Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response.","volume":"27","author":"Joshua","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"R14-20250808","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1001\/jama.2011.1880","article-title":"CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.","volume":"306","author":"Holmes","year":"2011","journal-title":"JAMA"},{"key":"R15-20250808","doi-asserted-by":"crossref","first-page":"105464","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105464","article-title":"CYP2C19 loss-of-function is associated with increased risk of ischemic stroke after transient ischemic attack in intracranial atherosclerotic disease.","volume":"30","author":"Patel","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R16-20250808","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2111749","article-title":"Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA.","author":"Wang","year":"2021","journal-title":"N Engl J Med"},{"key":"R17-20250808","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.","volume":"94","author":"Scott","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"R18-20250808","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"R19-20250808","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamaneurol.2018.4775","article-title":"Association between ABCB1 polymorphisms and outcomes of clopidogrel treatment in patients with minor stroke or transient ischemic attack: secondary analysis of a randomized clinical trial.","volume":"76","author":"Pan","year":"2019","journal-title":"JAMA Neurol"},{"key":"R20-20250808","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.repc.2018.03.015","article-title":"Myocardial infarction before and after the age of 45: possible role of platelet receptor polymorphisms.","volume":"37","author":"Pina-Cabral","year":"2018","journal-title":"Rev Port Cardiol (Engl Ed)"},{"key":"R21-20250808","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1182\/blood-2015-11-636472","article-title":"Protease-activated receptors in hemostasis.","volume":"128","author":"Nieman","year":"2016","journal-title":"Blood"},{"key":"R22-20250808","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1111\/jth.12715","article-title":"Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk.","volume":"12","author":"D\u2019Asti","year":"2014","journal-title":"J Thromb Haemost"},{"key":"R23-20250808","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature13083","article-title":"Structure of the human P2Y12 receptor in complex with an antithrombotic drug.","volume":"509","author":"Zhang","year":"2014","journal-title":"Nature"},{"key":"R24-20250808","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jcin.2018.01.263","article-title":"Platelet reactivity and risk of ischemic stroke after coronary drug-eluting stent implantation: from the ADAPT-DES Study.","volume":"11","author":"Giustino","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"R25-20250808","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1161\/01.STR.0000169922.79281.a5","article-title":"Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.","volume":"36","author":"Ziegler","year":"2005","journal-title":"Stroke"},{"key":"R26-20250808","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2478\/bjmg-2014-0072","article-title":"Effects of CYP2C19 and P2Y12 gene polymorphisms on clinical results of patients using clopidogrel after acute ischemic cerebrovascular disease.","volume":"17","author":"Sen","year":"2014","journal-title":"Balkan J Med Genet"},{"key":"R27-20250808","doi-asserted-by":"crossref","first-page":"24680","DOI":"10.1074\/jbc.M413411200","article-title":"Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation.","volume":"280","author":"Nanda","year":"2005","journal-title":"J Biol Chem"},{"key":"R28-20250808","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jacc.2006.10.050","article-title":"Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?","volume":"49","author":"Bliden","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R29-20250808","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","article-title":"Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.","volume":"46","author":"Gurbel","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R30-20250808","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/bcpt.13110","article-title":"Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients.","volume":"124","author":"Li","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R31-20250808","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10072-015-2407-7","article-title":"Comparison of VerifyNow P2Y12 and thrombelastography for assessing clopidogrel response in stroke patients in China.","volume":"37","author":"Lv","year":"2016","journal-title":"Neurol Sci"},{"key":"R32-20250808","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2018.01.057","article-title":"High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study.","volume":"259","author":"De Rosa","year":"2018","journal-title":"Int J Cardiol"},{"key":"R33-20250808","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.cr.7290272","article-title":"SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci.","volume":"15","author":"Shi","year":"2005","journal-title":"Cell Res"},{"key":"R34-20250808","first-page":"295","article-title":"Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation.","volume":"59","author":"Barragan","year":"2003","journal-title":"Catheter Cardiovasc Interv"},{"key":"R35-20250808","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/tpj.2015.17","article-title":"A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study.","volume":"16","author":"So","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"R36-20250808","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5551\/jat.33290","article-title":"Association of cytochrome P450 genetic variants with clopidogrel resistance and outcomes in acute ischemic stroke.","volume":"23","author":"Yi","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"R37-20250808","doi-asserted-by":"crossref","first-page":"e007811","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811","article-title":"Clopidogrel pharmacogenetics.","volume":"12","author":"Pereira","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"R38-20250808","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0092-8674(91)90261-V","article-title":"Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation.","volume":"64","author":"Vu","year":"1991","journal-title":"Cell"},{"key":"R39-20250808","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2002-07-2149","article-title":"An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN.","volume":"101","author":"Dupont","year":"2003","journal-title":"Blood"},{"key":"R40-20250808","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.thromres.2012.02.049","article-title":"Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response.","volume":"130","author":"Kreutz","year":"2012","journal-title":"Thromb Res"},{"key":"R41-20250808","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.thromres.2007.06.010","article-title":"Platelet PAR1 receptor density\u2013correlation to platelet activation response and changes in exposure after platelet activation.","volume":"121","author":"Ramstr\u00f6m","year":"2008","journal-title":"Thromb Res"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T12:01:57Z","timestamp":1754654517000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000462","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,23]]}}}